Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Shaukat on the PREEMPT CRC Blood-Based Assay for Average-Risk CRC

January 28th 2025

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer

January 27th 2025

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC

January 27th 2025

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Fruquintinib Plus TAS-102 Demonstrates Efficacy and Acceptable Toxicity in Pretreated mCRC

January 27th 2025

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

January 27th 2025

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Signatera ctDNA Assay Found to Influence Adjuvant Chemo Decision-Making in Stage II/III CRC

January 26th 2025

Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.

Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC

January 26th 2025

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.

Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC

January 25th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

Nivolumab Plus Ipilimumab Prolongs PFS vs Nivolumab Alone in MSI-H/dMMR mCRC

January 25th 2025

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

Dr Kopetz on the Phase 3 BREAKWATER Trial in Frontline Metastatic CRC

January 25th 2025

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Single-Cycle Neoadjuvant Pembrolizumab Is Efficacious, Safe in dMMR Colon Cancer

January 25th 2025

Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.

Trifluridine/Tipiracil Demonstrates DFS Benefit Over Placebo in Resected Stage IV CRC

January 25th 2025

Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.

Aspirin Is Associated With Reduced Recurrence Risk in PI3K+ CRC

January 25th 2025

Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.

ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer

January 25th 2025

ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.

Health Canada Green Lights Fruquintinib for Metastatic Colorectal Cancer

January 20th 2025

Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management

January 17th 2025

Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer.

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer

January 16th 2025

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

Dr Dasari on the Evolving Treatment Paradigm in mCRC

January 8th 2025

Arvind N. Dasari, MD, MS, discusses the roles for the FDA-approved agents fruquintinib and TAS-102 plus bevacizumab in the mCRC treatment paradigm.

Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC

January 8th 2025

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.